The Problem: Dr. Agarwal’s backed vision-tech startup had created a portable (VR based) glaucoma diagnostic device that was 80% cheaper. But only 3 units sold in six months. THE PROBLEM

A vision-tech startup backed by a leading eye care chain had created a portable glaucoma diagnostic device. The technology was solid. The economics were compelling: 80% cheaper than traditional equipment. But only 3 units sold in six months.

The company was targeting metro hospitals. The pitch was savings on operational space, cost, and time. Elite hospitals weren't biting. The portable format was being read as "low accuracy" by doctors who already had access to the latest equipment.

THE INSIGHT

"Portable" meant "compromise" to the wrong audience. Metro hospitals don't need cheaper equipment. They need the best equipment. The value proposition was backwards.

But independent ophthalmologists in tier 2 and tier 3 cities face a different problem. They can't afford expensive glaucoma diagnostic machines. They refer patients to bigger cities, losing both the patient relationship and revenue. For them, portable isn't a compromise. It's access to capabilities they couldn't otherwise afford.

The product was right. The target was wrong.

THE WORK

We met 50+ ophthalmologists across metros and tier 2 towns. The pattern was clear. Metro doctors saw "portable" as "not serious equipment." But doctors in smaller cities were interested, though skeptical about accuracy.

Shifted the entire go-to-market from elite hospitals to independent practitioners in tier 2 and tier 3 cities. Repositioned from "cost savings" to "accessibility backed by precision." The messaging focused on bringing metro-level diagnostics to smaller towns, with the backing and credibility of the parent eye care chain.

Built an activation strategy around webinars. Leveraged the parent company's brand authority and clinical credibility to overcome skepticism about the portable format. Let doctors see the device in action, understand the technology, ask technical questions.

THE OUTCOME

Sales jumped from 3 units to 48 units in 6 months. 80% of orders came from tier 2 and tier 3 towns, exactly as repositioned.

The company is now expanding its diagnostic portfolio using the same playbook: build for tier 2/3 accessibility, validate with metro credentials, activate through educational formats.